Karine Alcala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Karine Alcala has a total of 221 co-authors. Here are the top co-authors by number of shared publications:
- Hilary A. Robbins
International Agency for Research on Cancer Lyon France
26 shared publications - Mattias Johansson
Affiliation International Agency for Research on Cancer (IARC/WHO), Lyon, France
26 shared publications - David C. Muller
Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
19 shared publications - Ricardo Cortez Cardoso Penha
Genomic Epidemiology Branch, International Agency for Research on Cancer , Lyon
19 shared publications - Hana Zahed
Genomic Epidemiology Branch, International Agency for Research on Cancer , Lyon
18 shared publications - Karl Smith-Byrne
University of Oxford
18 shared publications
Latest Publications
- 30 June 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (8) , 1094-1106
Performance of Lung Cancer Risk Prediction Models in Different Racial and Ethnic Groups in the United States: Results From the Lung Cancer Cohort Consortium
Racial and ethnic disparities are a concern in lung cancer screening. To investigate the performance of risk prediction models to define screening eligibility across 4 U.S. racial and ethnic groups. Cohort study. United States, Lung Cancer Cohort Consortium. 641 830 participants aged 50 to 80 years with a smoking history from 12 U.S. cohorts, including 6390 Asian, 9781 Hispanic, 39 872 non-Hispanic Black, and 585 787 non-Hispanic White participants. Calibration and discrimination were quantified for 16 lung cancer prediction models. Then, screening-related metrics were calculated after applying model thresholds to select the same number of eligible participants as the 2021 criteria from the U.S. Preventive Services Task Force (USPSTF-2021). These included eligibility, sensitivity, and efficiency measured as estimated number needed to screen (NNS; the ratio between participants and lung cancer cases) for each strategy or prediction model in each racial and ethnic group. General patterns across the 16 models included substantial underestimation of lung cancer risk in non-Hispanic Black participants (expected-observed ratio < 0.75 for 11 of 16 models), lower discrimination in Asian participants than all other groups (13 of 16 models), and lower discrimination in non-Hispanic Black than non-Hispanic White participants (15 of 16 models). When a same-sized screening-eligible population as USPSTF-2021 (38.0%) was enforced, all risk-based strategies achieved better average estimated screening efficiency and reduced racial and ethnic differences in efficiency compared with USPSTF-2021. The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Model 2012 (PLCOm2012) and Life Years gained From Screening-Computed Tomography model (LYFS-CT) performed best (mean estimated NNS, 36.5 [SD, 8.8] and 40.1 [SD, 8.2], respectively). However, no strategy could simultaneously optimize eligibility, sensitivity, and efficiency while also reducing racial and ethnic differences. Smaller sample for Asian and Hispanic participants. To optimize efficiency and minimize its variation across racial and ethnic groups, risk-based strategies were superior to USPSTF criteria. Further optimization of prediction models for the diverse U.S. population is needed. U.S. National Cancer Institute, Lung Cancer Research Foundation, and Cancer Research UK.
- 30 June 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (8) , 1094-1106
Performance of Lung Cancer Risk Prediction Models in Different Racial and Ethnic Groups in the United States: Results From the Lung Cancer Cohort Consortium
Racial and ethnic disparities are a concern in lung cancer screening. To investigate the performance of risk prediction models to define screening eligibility across 4 U.S. racial and ethnic groups. Cohort study. United States, Lung Cancer Cohort Consortium. 641 830 participants aged 50 to 80 years with a smoking history from 12 U.S. cohorts, including 6390 Asian, 9781 Hispanic, 39 872 non-Hispanic Black, and 585 787 non-Hispanic White participants. Calibration and discrimination were quantified for 16 lung cancer prediction models. Then, screening-related metrics were calculated after applying model thresholds to select the same number of eligible participants as the 2021 criteria from the U.S. Preventive Services Task Force (USPSTF-2021). These included eligibility, sensitivity, and efficiency measured as estimated number needed to screen (NNS; the ratio between participants and lung cancer cases) for each strategy or prediction model in each racial and ethnic group. General patterns across the 16 models included substantial underestimation of lung cancer risk in non-Hispanic Black participants (expected-observed ratio < 0.75 for 11 of 16 models), lower discrimination in Asian participants than all other groups (13 of 16 models), and lower discrimination in non-Hispanic Black than non-Hispanic White participants (15 of 16 models). When a same-sized screening-eligible population as USPSTF-2021 (38.0%) was enforced, all risk-based strategies achieved better average estimated screening efficiency and reduced racial and ethnic differences in efficiency compared with USPSTF-2021. The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Model 2012 (PLCOm2012) and Life Years gained From Screening-Computed Tomography model (LYFS-CT) performed best (mean estimated NNS, 36.5 [SD, 8.8] and 40.1 [SD, 8.2], respectively). However, no strategy could simultaneously optimize eligibility, sensitivity, and efficiency while also reducing racial and ethnic differences. Smaller sample for Asian and Hispanic participants. To optimize efficiency and minimize its variation across racial and ethnic groups, risk-based strategies were superior to USPSTF criteria. Further optimization of prediction models for the diverse U.S. population is needed. U.S. National Cancer Institute, Lung Cancer Research Foundation, and Cancer Research UK.
- Open Access
- 10 February 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (2) , e1004906
Systematic assessment of obesity-related risk factors in renal cancer etiology: A longitudinal risk and Mendelian randomization analysis
Background: Excess body adiposity is an established cause of renal cancer, but underlying molecular pathways mediating this relationship remain unclear. This study aimed to systematically evaluate a panel of obesity-related risk factors as potential mediators in renal cancer etiology. Methods and findings: We used two complementary approaches to evaluate obesity-related risk factors in renal cancer etiology: (i) direct risk factor assessment in longitudinal cohorts and (ii) genetically proxied risk factors through two-sample Mendelian randomization (MR). Direct risk-factor association-analyses (i.e., cohort analyses) were based on the UK Biobank cohort study (472,337 cohort participants, including 1,382 incident renal cancer cases diagnosed during 5,586,414 person years of follow-up) and the Northern Sweden Health and Disease Study (NSHDS) for fasting insulin (204 pairs of cases and controls, ongoing recruitment and follow-up since 1985). We used Cox proportional hazards regression models to evaluate the association between risk factors and renal cancer risk with adjustment for age, sex, center of recruitment, education, smoking and alcohol drinking status. Two-sample MR analyses were based on a genome-wide association study (GWAS) of renal cancer (27,213 cases, 486,846 controls). We used the inverse-variance weighted (IVW) approach to estimate the association between risk factors and renal cancer risk. Mediation analyses were performed for traits displaying directionally consistent associations with renal cancer risk in both the cohort and MR analyses using the product method. We found consistent positive associations with renal cancer risk for fasting insulin (odds ratio per standard deviation increment [OR MR ]: 2.24, 95% confidence interval [95% CI]: 1.19, 4.22; p = 0.01; hazard ratio per standard deviation increment [HR cohort ]: 1.43, 95% CI: 1.02, 2.00; p = 0.04), triglycerides (OR MR : 1.11, 95% CI: 1.05, 1.17; p < 0.001, HR cohort : 1.23, 95% CI: 1.11, 1.38; p < 0.001), diastolic blood pressure (DBP) (OR MR : 1.14, 95% CI: 1.04, 1.26; p < 0.001, HR cohort : 1.11, 95% CI: 1.05, 1.17; p < 0.001) and consistent inverse associations with renal cancer risk for sex-hormone binding globulin (SHBG) (OR MR : 0.80, 95% CI: 0.70, 0.90; p < 0.001, HR cohort : 0.67, 95% CI: 0.58, 0.76; p < 0.001) and high-density lipoprotein (HDL) cholesterol (OR MR : 0.93, 95% CI: 0.88, 0.98; p < 0.001, HR cohort : 0.72, 95% CI: 0.66, 0.77; p < 0.001). The main limitation of this study was that we had limited statistical power to evaluate some risk factors. Conclusions: Our study highlights roles for fasting insulin, HDL cholesterol, DBP, triglycerides and SHBG in mediating the relationship between body adiposity and renal cancer risk.
- 10 February 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (2) , e1004906
Open AccessSystematic assessment of obesity-related risk factors in renal cancer etiology: A longitudinal risk and Mendelian randomization analysis
Background: Excess body adiposity is an established cause of renal cancer, but underlying molecular pathways mediating this relationship remain unclear. This study aimed to systematically evaluate a panel of obesity-related risk factors as potential mediators in renal cancer etiology. Methods and findings: We used two complementary approaches to evaluate obesity-related risk factors in renal cancer etiology: (i) direct risk factor assessment in longitudinal cohorts and (ii) genetically proxied risk factors through two-sample Mendelian randomization (MR). Direct risk-factor association-analyses (i.e., cohort analyses) were based on the UK Biobank cohort study (472,337 cohort participants, including 1,382 incident renal cancer cases diagnosed during 5,586,414 person years of follow-up) and the Northern Sweden Health and Disease Study (NSHDS) for fasting insulin (204 pairs of cases and controls, ongoing recruitment and follow-up since 1985). We used Cox proportional hazards regression models to evaluate the association between risk factors and renal cancer risk with adjustment for age, sex, center of recruitment, education, smoking and alcohol drinking status. Two-sample MR analyses were based on a genome-wide association study (GWAS) of renal cancer (27,213 cases, 486,846 controls). We used the inverse-variance weighted (IVW) approach to estimate the association between risk factors and renal cancer risk. Mediation analyses were performed for traits displaying directionally consistent associations with renal cancer risk in both the cohort and MR analyses using the product method. We found consistent positive associations with renal cancer risk for fasting insulin (odds ratio per standard deviation increment [OR MR ]: 2.24, 95% confidence interval [95% CI]: 1.19, 4.22; p = 0.01; hazard ratio per standard deviation increment [HR cohort ]: 1.43, 95% CI: 1.02, 2.00; p = 0.04), triglycerides (OR MR : 1.11, 95% CI: 1.05, 1.17; p < 0.001, HR cohort : 1.23, 95% CI: 1.11, 1.38; p < 0.001), diastolic blood pressure (DBP) (OR MR : 1.14, 95% CI: 1.04, 1.26; p < 0.001, HR cohort : 1.11, 95% CI: 1.05, 1.17; p < 0.001) and consistent inverse associations with renal cancer risk for sex-hormone binding globulin (SHBG) (OR MR : 0.80, 95% CI: 0.70, 0.90; p < 0.001, HR cohort : 0.67, 95% CI: 0.58, 0.76; p < 0.001) and high-density lipoprotein (HDL) cholesterol (OR MR : 0.93, 95% CI: 0.88, 0.98; p < 0.001, HR cohort : 0.72, 95% CI: 0.66, 0.77; p < 0.001). The main limitation of this study was that we had limited statistical power to evaluate some risk factors. Conclusions: Our study highlights roles for fasting insulin, HDL cholesterol, DBP, triglycerides and SHBG in mediating the relationship between body adiposity and renal cancer risk.
- Open Access
- 1 December 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (4) , 636-642
Lymphocyte count and risk of chronic lymphocytic leukemia
Background: Elevated absolute lymphocyte count is often used as a first indication for diagnostic investigation of chronic lymphocytic leukemia (CLL). The absolute risk of CLL as a function of age, sex, and absolute lymphocyte count has not been described. Methods: We used information about prediagnostic absolute lymphocyte cell count on 475 399 longitudinally followed research participants from UK Biobank, with a median follow-up of 11.6 years, during which 854 participants were diagnosed with CLL. A CLL risk model was developed based on sex, age at recruitment, and prediagnostic absolute lymphocyte count using flexible parametric survival modelling. Results: Compared with research participants who had absolute lymphocyte counts below 2 × 109/L, the risk of CLL was almost 8 times higher for individuals with absolute lymphocyte counts of 3 to 4 × 109/L (hazard ratio = 7.76, 95% CI = 6.24 to 9.65). The absolute risk of CLL was 2-fold higher in male than in female individuals. For 60-year-old persons with absolute lymphocyte counts of 5 ×109/L, 10-year CLL risk was estimated at 6.5% (95% CI = 5.6% to 7.5%) for men and 3.5% (95% CI = 3.0% to 4.1%) for women. The 10-year risk of CLL for participants with absolute lymphocyte counts of 5 ×109/L varied between 0.91% (95% CI = 0.68% to 1.2%) for a 40-year-old woman and 12% (95% CI = 11% to 15%) for a 70-year-old man. Conclusion: The absolute risk of CLL is strongly influenced by age, sex, and absolute lymphocyte count. A crude absolute lymphocyte count cutoff to indicate further investigation for CLL without taking age and sex into consideration will identify some individuals who are at low risk. These results may be considered when establishing guidelines for clinical management in patients with elevated absolute lymphocyte counts.
- 1 December 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (4) , 636-642
Open AccessLymphocyte count and risk of chronic lymphocytic leukemia
Background: Elevated absolute lymphocyte count is often used as a first indication for diagnostic investigation of chronic lymphocytic leukemia (CLL). The absolute risk of CLL as a function of age, sex, and absolute lymphocyte count has not been described. Methods: We used information about prediagnostic absolute lymphocyte cell count on 475 399 longitudinally followed research participants from UK Biobank, with a median follow-up of 11.6 years, during which 854 participants were diagnosed with CLL. A CLL risk model was developed based on sex, age at recruitment, and prediagnostic absolute lymphocyte count using flexible parametric survival modelling. Results: Compared with research participants who had absolute lymphocyte counts below 2 × 109/L, the risk of CLL was almost 8 times higher for individuals with absolute lymphocyte counts of 3 to 4 × 109/L (hazard ratio = 7.76, 95% CI = 6.24 to 9.65). The absolute risk of CLL was 2-fold higher in male than in female individuals. For 60-year-old persons with absolute lymphocyte counts of 5 ×109/L, 10-year CLL risk was estimated at 6.5% (95% CI = 5.6% to 7.5%) for men and 3.5% (95% CI = 3.0% to 4.1%) for women. The 10-year risk of CLL for participants with absolute lymphocyte counts of 5 ×109/L varied between 0.91% (95% CI = 0.68% to 1.2%) for a 40-year-old woman and 12% (95% CI = 11% to 15%) for a 70-year-old man. Conclusion: The absolute risk of CLL is strongly influenced by age, sex, and absolute lymphocyte count. A crude absolute lymphocyte count cutoff to indicate further investigation for CLL without taking age and sex into consideration will identify some individuals who are at low risk. These results may be considered when establishing guidelines for clinical management in patients with elevated absolute lymphocyte counts.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Kidney Function and Risk of Renal Cell Carcinoma
Supplemental figure 2 shows the estimated 5-years risk of RCC with eGFRcreat_cystC by common RCC risk factors across ages for males.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Kidney Function and Risk of Renal Cell Carcinoma
Supplemental figure 2 shows the estimated 5-years risk of RCC with eGFRcreat_cystC by common RCC risk factors across ages for males.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Kidney Function and Risk of Renal Cell Carcinoma
Supplemental figure 4 shows the estimated 5-years risk of RCC with eGFRcreat-cystC by combination of common risk factors across ages, by sex.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Kidney Function and Risk of Renal Cell Carcinoma
Supplemental figure 4 shows the estimated 5-years risk of RCC with eGFRcreat-cystC by combination of common risk factors across ages, by sex.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Kidney Function and Risk of Renal Cell Carcinoma
Supplemental table 2 shows the betas estimates and standard errors from the original risk model, the recalibrated model without and with CRP, and the updated model with eGFR.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Kidney Function and Risk of Renal Cell Carcinoma
Supplemental table 2 shows the betas estimates and standard errors from the original risk model, the recalibrated model without and with CRP, and the updated model with eGFR.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Kidney Function and Risk of Renal Cell Carcinoma
Supplemental figure 3 shows the estimated 1-year and 5-years risk of RCC with eGFRcreat_cystC by common RCC risk factors across ages for females.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Kidney Function and Risk of Renal Cell Carcinoma
Supplemental figure 3 shows the estimated 1-year and 5-years risk of RCC with eGFRcreat_cystC by common RCC risk factors across ages for females.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Kidney Function and Risk of Renal Cell Carcinoma
Supplemental figure 5 shows the comparison of the original and updated 1-year and 5-years risk of RCC for the participants with and without RCC diagnosis in the training and testing set of UKB.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Kidney Function and Risk of Renal Cell Carcinoma
Supplemental figure 5 shows the comparison of the original and updated 1-year and 5-years risk of RCC for the participants with and without RCC diagnosis in the training and testing set of UKB.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Kidney Function and Risk of Renal Cell Carcinoma
Supplemental table 1 shows the characteristics of the studied population for the etiology analysis.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Kidney Function and Risk of Renal Cell Carcinoma
Supplemental table 1 shows the characteristics of the studied population for the etiology analysis.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary File 1 from Kidney Function and Risk of Renal Cell Carcinoma
Supplementary File 1 contains the risk score.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary File 1 from Kidney Function and Risk of Renal Cell Carcinoma
Supplementary File 1 contains the risk score.